EP0375471A3 - Utilisation de 1,2,3,4-tétrahydro-acridines pour le traitement du SIDA, et composés - Google Patents

Utilisation de 1,2,3,4-tétrahydro-acridines pour le traitement du SIDA, et composés Download PDF

Info

Publication number
EP0375471A3
EP0375471A3 EP19890402687 EP89402687A EP0375471A3 EP 0375471 A3 EP0375471 A3 EP 0375471A3 EP 19890402687 EP19890402687 EP 19890402687 EP 89402687 A EP89402687 A EP 89402687A EP 0375471 A3 EP0375471 A3 EP 0375471A3
Authority
EP
European Patent Office
Prior art keywords
tetrahydro
acridines
aids
compounds
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19890402687
Other languages
German (de)
English (en)
Other versions
EP0375471A2 (fr
EP0375471B1 (fr
Inventor
François DIETLIN
Danièle Fredj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STE CIVILE DE RECHERCHE NEWPHARM
Original Assignee
STE CIVILE DE RECHERCHE NEWPHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STE CIVILE DE RECHERCHE NEWPHARM filed Critical STE CIVILE DE RECHERCHE NEWPHARM
Publication of EP0375471A2 publication Critical patent/EP0375471A2/fr
Publication of EP0375471A3 publication Critical patent/EP0375471A3/fr
Application granted granted Critical
Publication of EP0375471B1 publication Critical patent/EP0375471B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte au domaine de la chimie thérapeutique.
Elle a pour objet des compositions pharmaceutiques assurant la regénération des lymphocytes T4 ou l'augmentation de leur nombre chez des sujets présentant un syndrome immuno-déficitaire qui renferment, à titre de principe actif, la 9-amino 1,2,3,4-Tétrahydro acridine ou un de ses sels ou un de ses précurseurs biologiques.
L'invention concerne aussi, à titre de produits nouveaux, les précurseurs biologiques de la 9-amino 1,2,3,4-Tétrahydro acridine.
EP89402687A 1988-12-19 1989-09-29 Utilisation de 1,2,3,4-tétrahydro-acridines pour le traitement du SIDA, et composés Expired - Lifetime EP0375471B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8816749 1988-12-19
FR888816749A FR2640508B1 (fr) 1988-12-19 1988-12-19 Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire

Publications (3)

Publication Number Publication Date
EP0375471A2 EP0375471A2 (fr) 1990-06-27
EP0375471A3 true EP0375471A3 (fr) 1992-07-08
EP0375471B1 EP0375471B1 (fr) 1996-04-10

Family

ID=9373109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89402687A Expired - Lifetime EP0375471B1 (fr) 1988-12-19 1989-09-29 Utilisation de 1,2,3,4-tétrahydro-acridines pour le traitement du SIDA, et composés

Country Status (19)

Country Link
EP (1) EP0375471B1 (fr)
JP (1) JPH02258722A (fr)
KR (1) KR900009075A (fr)
AP (1) AP125A (fr)
AT (1) ATE136463T1 (fr)
AU (2) AU4686189A (fr)
CA (1) CA2005925C (fr)
DE (1) DE68926222D1 (fr)
DK (1) DK646489A (fr)
FR (1) FR2640508B1 (fr)
HU (1) HU213510B (fr)
IL (1) IL92759A (fr)
MA (1) MA21964A1 (fr)
MY (1) MY106032A (fr)
NZ (1) NZ231854A (fr)
OA (1) OA09250A (fr)
PT (1) PT92620B (fr)
TN (1) TNSN89135A1 (fr)
ZA (1) ZA899733B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155226A (en) * 1991-02-19 1992-10-13 Hoechst-Roussel Pharmaceuticals Incorporated Method for the preparation of 9-amino-1,2,3,4-tetrahydroacridine
EP0509401A1 (fr) * 1991-04-19 1992-10-21 Hoechst-Roussel Pharmaceuticals Incorporated Utilisation de 9-amino-1,2,3,4-tetrahydroacridine-1-ol et des composés apparentés pour le traitement du SIDA
RU2036198C1 (ru) * 1993-04-01 1995-05-27 Товарищество с ограниченной ответственностью "Полисан" N-МЕТИЛ-N-( α,D -ГЛЮКОПИРАНОЗИЛ) АММОНИЯ-2-(АКРИДОН-9-ОН-10-ИЛ)АЦЕТАТ(ЦИКЛОФЕРОН), ОБЛАДАЮЩИЙ ИНТЕРФЕРОНОГЕННОЙ, ПРОТИВОВИРУСНОЙ, В ТОМ ЧИСЛЕ АНТИВИЧ, АНТИПАРАЗИТАРНОЙ, АНТИПРОМОТОРНОЙ И РАДИОПРОТЕКТИВНОЙ АКТИВНОСТЬЮ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003804A2 (fr) * 1986-11-21 1988-06-02 Max-Planck-Gesellschaft Zur Förderung Der Wissensc Procede pour traiter des infections virales chez des humains, et compositions a cet effet
WO1988005657A1 (fr) * 1987-01-28 1988-08-11 Chu Chung K Composition anti-retrovirale de 3'-azido-2',3'-didesoxyuridine
WO1988007854A1 (fr) * 1987-04-10 1988-10-20 United States Of America, Represented By The Unite Nouveaux agents anti-retroviraux et systeme d'apport
EP0306825A1 (fr) * 1987-09-08 1989-03-15 Hoechst-Roussel Pharmaceuticals Incorporated N-[Alkylidène substitué] tétrahydro-1,2,3,4 acridine-amines-9, procédé pour leur préparation et leur application comme médicaments
WO1990014086A1 (fr) * 1989-05-25 1990-11-29 Debiopharm S.A. Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985430A (en) * 1987-12-03 1991-01-15 Mitsubishi Kasei Corporation 9-acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
US4999358A (en) * 1989-06-26 1991-03-12 Hoechst-Roussel Pharmaceuticals Inc. (1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003804A2 (fr) * 1986-11-21 1988-06-02 Max-Planck-Gesellschaft Zur Förderung Der Wissensc Procede pour traiter des infections virales chez des humains, et compositions a cet effet
WO1988005657A1 (fr) * 1987-01-28 1988-08-11 Chu Chung K Composition anti-retrovirale de 3'-azido-2',3'-didesoxyuridine
WO1988007854A1 (fr) * 1987-04-10 1988-10-20 United States Of America, Represented By The Unite Nouveaux agents anti-retroviraux et systeme d'apport
EP0306825A1 (fr) * 1987-09-08 1989-03-15 Hoechst-Roussel Pharmaceuticals Incorporated N-[Alkylidène substitué] tétrahydro-1,2,3,4 acridine-amines-9, procédé pour leur préparation et leur application comme médicaments
WO1990014086A1 (fr) * 1989-05-25 1990-11-29 Debiopharm S.A. Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
6TH INTERNATIONAL CONFERENCE AIDS, 20th-23rd June 1990, abrégé de conférence no. S.B. 457, pages 200-201; M. YOULE et al.: "Open study of tacrine hydrochloride in Hiv P24 antigen positive patients", Abrege. *
6TH INTERNATIONAL CONFERENCE AIDS, 20th-23rd June 1990, abrégé de conférence no. S.B. 458, pages 200-201; G. FREDJ et al.: "Follow-up of Hiv infected post Azt patients treated by tacrine (THA), abrege. *
BIOMEDICINE & PHARMACOTHERAPY, vol. 43, no. 4, 1989, pages 235-236, Elsevier, Paris, FR; G. MATHé et al.: "Amino acridines action on Friend's retrovirus in relation to their molecular ionization", Revendications 1-28. *
INDIAN JOURNAL OF CHEMISTRY, vol. 26b, no. 4, avril 1987, pages 330-334, Publications & Information Directorate, CSIR, New Delhi, IN; P. ASTHANA et al.: "Synthesis of 9-Substituted-oxy Acridine & 1,2,3,4-tetrahydroacridine derivatives as potential biodynamic agents", Article en entier, page 333. *
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY THERAPY AND TOXICOLOGY, vol. 27, no. 8, août 1989, pages 408-410; G. FREDJ et al.: "Tetrahydroaminoacridine in HIV infections", Article en entier. *
JOURNAL DE CHIMIE PHYSIQUE, vol. 78, no. 6, 1981, pages 527-530; R. FAURE et al.: "Etude par résonance magnétique nucléaire du carbone 13 de quelques tetrahydro-1,2,3,4 acridines substituées en position 9", Page 527. *
THE LANCET, vol. 1, 16 avril 1988, page 887; D.J. AMES et al.: "Hepatotoxicity of tetrahydroacridine", Article en entier. *

Also Published As

Publication number Publication date
MY106032A (en) 1995-02-28
CA2005925C (fr) 2002-03-26
DE68926222D1 (de) 1996-05-15
HU213510B (en) 1997-07-28
AP8900157A0 (en) 1990-01-31
AP125A (en) 1991-03-19
EP0375471A2 (fr) 1990-06-27
AU666725B2 (en) 1996-02-22
ZA899733B (en) 1991-04-24
ATE136463T1 (de) 1996-04-15
CA2005925A1 (fr) 1990-06-19
PT92620A (pt) 1990-06-29
IL92759A0 (en) 1990-09-17
TNSN89135A1 (fr) 1991-02-04
HU896683D0 (en) 1990-02-28
FR2640508B1 (fr) 1994-07-01
EP0375471B1 (fr) 1996-04-10
OA09250A (fr) 1992-06-30
JPH02258722A (ja) 1990-10-19
AU3980693A (en) 1993-08-19
DK646489D0 (da) 1989-12-19
FR2640508A1 (fr) 1990-06-22
MA21964A1 (fr) 1991-07-01
PT92620B (pt) 1995-09-12
NZ231854A (en) 1993-01-27
KR900009075A (ko) 1990-07-02
AU4686189A (en) 1990-06-21
IL92759A (en) 1994-06-24
DK646489A (da) 1990-06-20

Similar Documents

Publication Publication Date Title
OA09807A (fr) "Dérivé de la 5H-pyrrolo[ 3,4-b]pyrazine optiquement actif. Sa préparation et les compositions pharmaceutiques qui le contiennent".
FI881579A7 (fi) Syövänvastainen terapia ja sytotoksiset lääkkeet sen suorittamiseksi.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
FI951600A7 (fi) Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
TNSN97091A1 (fr) CONJUGUE PEG-IFN α PHYSIOLOGIQUEMENT ACTIF, PROCEDE POUR SA PREPARATION, COMPOSITIONS PHARMACEUTIQUES LE CONTENANT ET LEUR UTILISATION
FI884384L (fi) Yliannostuksen estolla varustettu sumutinpakkaus fysiologisesti aktiivisten aineiden itseannostelemiseksi
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
CA2197702A1 (fr) Utilisation d'un 2-amino-alcane-1,3-diol en tant qu'agent destine a freiner la chute des cheveux et/ou induire et stimuler leur croissance
CA2330807A1 (fr) Utilisation d'inhibiteurs de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
CA2222698A1 (fr) Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
FR2600891B1 (fr) Produit pharmaceutique pour la stimulation de l'apprentissage et l'amelioration de la memoire contenant comme principe actif, le chlorhydrate de 9-amino-2,3, 5,6,7,8,-hexahydro-14-cyclopenta(b)quinoline monohydrate
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
RU94002476A (ru) Лекарственное средство
EP0375471A3 (fr) Utilisation de 1,2,3,4-tétrahydro-acridines pour le traitement du SIDA, et composés
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
ATE139446T1 (de) Arzneimittel zur behandlung von erregungszuständen und nervendysfunktionen
EP0305276A3 (fr) Application de l'amino-2 trifluorométhoxy-6 benzothiazole pour obtenir un médicament destiné au traitement de la schizophrénie
IT8919637A0 (it) Isomero otticamente attivo della cloperastina avente attivita' antitussiva, processo per la sua preparazione e composizioni farmaceutiche che lo contengono.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19921231

17Q First examination report despatched

Effective date: 19941114

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 19960410

Ref country code: GB

Effective date: 19960410

Ref country code: AT

Effective date: 19960410

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19960410

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960410

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960410

REF Corresponds to:

Ref document number: 136463

Country of ref document: AT

Date of ref document: 19960415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 68926222

Country of ref document: DE

Date of ref document: 19960515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19960711

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19960901

Year of fee payment: 8

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
GBV Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed]

Effective date: 19960410

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19961029

Year of fee payment: 8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19971104

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980930

BERE Be: lapsed

Owner name: STE CIVILE DE RECHERCHE NEWPHARM

Effective date: 19980930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040929

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060531